Vaccine News and Research

Latest Vaccine News and Research

FluGen's CHO-cell-based production system generates egg-free, 2009 H1N1 influenza vaccine virus

FluGen Inc., an emerging leader in the development, production and delivery of influenza vaccines, today announced that its proprietary CHO-cell-based production system has generated novel 2009 H1N1 influenza vaccine virus without the use of eggs during any step of production.

30 Oct 2009

All Canadians need to be immunized against H1N1: CPHA

The Canadian Public Health Association (CPHA) announced today that it is encouraging Canadians to get the H1N1 vaccination. To help people make an informed choice, it is launching a new online portal of information.

30 Oct 2009

UCLA Kaiser Permanente Center expands to eliminate health disparities

The UCLA School of Public Health has received a $5.2 million gift from Kaiser Permanente to endow the UCLA Kaiser Permanente Center for Health Equity. The center, formerly known as the Center to Eliminate Health Disparities, is dedicated to improving the health of underserved populations through research, community collaboration and leadership development.

30 Oct 2009

Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine

Dynavax Technologies Corporation today announced the first clinical data for HEPLISAVTM investigational hepatitis B vaccine in chronic kidney disease patients.

30 Oct 2009

New online education course on H1N1 vaccination now available

mdBriefCase Inc., in collaboration with the Public Health Agency of Canada (PHAC), is pleased to provide a new online education course on H1N1 vaccination for health professionals.

30 Oct 2009

New campaign offers information and resources on seasonal and H1N1 flu prevention

Blue Cross Blue Shield of Arizona (BCBSAZ) says “Get the facts, not the flu,” in a new campaign that launches today at azblue.com/Flu. The flu campaign offers its members, employer groups and Arizona residents information and resources on seasonal and H1N1 flu prevention and immunization.

30 Oct 2009

Risk of serious flu-related sickness far outpaces risk of injectable vaccine in pregnant women

Pregnant women who catch the flu are at serious risk for flu-related complications, including death, and that risk far outweighs the risk of possible side effects from injectable vaccines containing killed virus, according to an extensive review of published research and data from previous flu seasons.

30 Oct 2009

U.S. won't donate H1N1 vaccine to developing countries until 'at-risk' Americans receive vaccine

The U.S. will hold off on donating H1N1 (swine flu) vaccine stockpiles to developing countries until "at-risk Americans" receive the vaccine, HHS Secretary Kathleen Sebelius said Wednesday, Agence France-Presse reports

30 Oct 2009

Obama administration hits reset button in wake of flu vaccine shortage

Obama administration officials are working to control the H1N1 flu message after shortages have forced many to wait for the swine flu vaccine.

29 Oct 2009

GSK will ensure experimental malaria vaccine is affordable, CEO says

GlaxoSmithKline CEO Andrew Witty said Wednesday the company would ensure that if an experimental malaria vaccine works, it would be priced reasonably, Reuters reports. "The vaccine, called Mosquirix [or RTS,S] and the first malaria shot to make it to final-stage trials, is creating a buzz ahead of a conference of 1,500 malaria experts in Nairobi next week," writes Reuters.

29 Oct 2009

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

AstraZeneca, Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million.

29 Oct 2009

Today's opinions and editorials

The federal government could treat Indian Country, at least for health programs, as the 51st state. This seems to me a practical application of the nation-to-nation relationship (Mark Trahant, 10/29).

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

First Edition: October 29, 2009

Today's headlines are all about the unveiling of the House health bill -- expected later this morning.

29 Oct 2009

Centene takes proactive approach to prevent influenza virus through its Fluvention program

Centene Corporation takes a proactive approach with education around how to prevent the influenza virus each year through its FluventionTM program.

29 Oct 2009

Bio-Pharmaceutical Summit 2009 to be held in China

Biotechnology is an emerging industry to which many countries are attaching great importance. China is determined to grasp the great opportunities brought by the biotechnology revolution. Biotech industry will become a pillar of China’s hi-tech sector, in which bio-pharmaceutical is playing a leading role.

29 Oct 2009

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

29 Oct 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. (“Amarantus”) and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.

29 Oct 2009

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

29 Oct 2009

Vaccine News and Research

Latest Vaccine News and Research

FluGen's CHO-cell-based production system generates egg-free, 2009 H1N1 influenza vaccine virus

All Canadians need to be immunized against H1N1: CPHA

UCLA Kaiser Permanente Center expands to eliminate health disparities

Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine

New online education course on H1N1 vaccination now available

New campaign offers information and resources on seasonal and H1N1 flu prevention

Risk of serious flu-related sickness far outpaces risk of injectable vaccine in pregnant women

U.S. won't donate H1N1 vaccine to developing countries until 'at-risk' Americans receive vaccine

Obama administration hits reset button in wake of flu vaccine shortage

GSK will ensure experimental malaria vaccine is affordable, CEO says

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

Today's opinions and editorials

Third-quarter 2009 financial results of Antigenics announced

First Edition: October 29, 2009

Centene takes proactive approach to prevent influenza virus through its Fluvention program

Bio-Pharmaceutical Summit 2009 to be held in China

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in